1387634-86-7

Basic information

• Product Name: 1-(3-bromo-2,6-difluorophenyl)ethan-1-ol
• Synonyms: 1-(3-bromo-2,6-difluorophenyl)ethan-1-ol
• CAS NO: 1387634-86-7
• Molecular Weight: 237.044
• Mol File: 1387634-86-7.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-(3-bromo-2,6-difluorophenyl)ethan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-bromo-2,6-difluorophenyl)ethan-1-ol(1387634-86-7)
• EPA Substance Registry System: 1-(3-bromo-2,6-difluorophenyl)ethan-1-ol(1387634-86-7)

Safety Data

• Hazardous Substances Data: 1387634-86-7(Hazardous Substances Data)

Upstream product

• 398456-82-1 3-bromo-2,6-difluoro-benzaldehyde 
• 75-16-1 methylmagnesium bromide 

Downstream Products

• 1387634-87-8 1-(3-bromo-2,6-difluorophenyl)ethan-1-one 
• 1600511-68-9 (+/-)-(E)-N-(1-(3-Bromo-2,6-difluorophenyl)ethylidene)-2-methylpropane-2-sulfinamide 
• 1600511-70-3 N-(2-(3-bromo-2,6-difluorophenyl)-1-((2-cyanopropan-2-yl)sulfonyl)propan-2-yl)-2-methylpropane-2-sulfinamide 

Relevant articles and documents

INHIBITORS OF ENL/AF9 YEATS

Methods and compositions for treating leukemia are disclosed. Acylated 6-aminoindoles, acylated 6-aminopyrrolopyridines and acylated 3-aminopyrrolo[3,2-c]pyridazines of the following formula inhibit ENL/AF9 YEATS and are therefore useful for treating leukemia.

COMBINATION THERAPIES WITH IRE1 SMALL MOLECULE INHIBITORS

Provided herein are methods of using IRE1 small molecule inhibitors in combination therapies for treating cancer in a subject. The IRE1 small molecule inhibitors described herein may be used in combination therapies for treating solid and hematologic cancers.

IRE1 SMALL MOLECULE INHIBITORS

Provided herein are small molecule inhibitors for the targeting or IRE1 protein family members. Binding may be direct or indirect. Further provided herein are methods of using IRE1 small molecule inhibitors for use in treating or ameliorating cancer in a subject. Moreover, IRE1 small molecule inhibitors described herein are for the treatment of cancer, where the cancer is a solid or hematologic cancer.